Although the PACIFIC trial established PD-L1 blockade with durvalumab as effective consolidation therapy following chemoradiotherapy in unresectable stage III non-small cell lung cancer (NSCLC), this strategy has not been investigated in TC [76]. Here, CD274 is linked to non-small cell lung carcinoma.